Skip to main content
. 2022 Dec 7;11(24):3958. doi: 10.3390/cells11243958

Figure 2.

Figure 2

Figure 2

EZH2 could be a potential biomarker for SALI and NSCLC. (A,B) Western blot assay was performed to assess the EZH2 expression level in healthy donors (HDs) and septic patients. The fold expression was measured by densitometric analysis. (C,D) Representative IHC staining of EZH2 in normal and NSCLC tissues from the HPA database. (E) ROC curve of EZH2 in NSCLC patients from the TCGA database. (F,G) Western blot assay was performed to assess the EZH2 expression level in LPS-induced PBMCs and A549. The fold expression was measured by densitometric analysis. Values are expressed as mean ± SD. #### p < 0.001, relative to the control group, n = 3.